Clinical Trials Logo

Depressive Disorder, Treatment-Resistant clinical trials

View clinical trials related to Depressive Disorder, Treatment-Resistant.

Filter by:

NCT ID: NCT03833063 Not yet recruiting - Clinical trials for Major Depressive Disorder

Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression

BOTDEP
Start date: March 1, 2019
Phase: Phase 1
Study type: Interventional

The effectiveness of glabellar injection of botulinum toxin type A (BTA) in treating depression has not yet been investigated in elderly patients. The study aims in addressing the question if glabellar injection of BTA is effective in treating geriatric depression.

NCT ID: NCT03829579 Available - Clinical trials for Depressive Disorder, Treatment-Resistant

Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

Start date: n/a
Phase:
Study type: Expanded Access

This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have exhausted all other treatment options, including all alternative treatment options with marketed therapies.

NCT ID: NCT03786614 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Antidepressant Discontinuation in Treatment Resistant Depression

Start date: February 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effects on depressive symptoms of subjects who discontinue serotonergic antidepressants (a certain type of antidepressant, such as Prozac, that works on serotonin receptors in the brain) with the effects on depressive symptoms of subjects who continue to take serotonergic antidepressants. During this study, subjects will also be presented with the opportunity to undergo genetic testing for the serotonin gene transporter which has a short or long form. This is being done because it has been demonstrated that genetic testing improves outcome while treating treatment-resistant depression.

NCT ID: NCT03775200 Not yet recruiting - Clinical trials for Treatment Resistant Depression

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

P-TRD
Start date: December 2018
Phase: Phase 2
Study type: Interventional

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

NCT ID: NCT03756129 Not yet recruiting - Clinical trials for Depressive Disorder, Treatment-Resistant

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Start date: February 8, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study will be conducted in the US and in Europe (Spain and Czech Republic). The MIJ821 will be administered via infusion on a weekly or bi-weekly basis. The efficacy will be measured after 24 hours using a specific golden standard scale, the Montgomery-Asberg Depression Rating Scale. The study duration is 6 weeks of treatment plus 1 month of follow up period.

NCT ID: NCT03742557 Recruiting - Clinical trials for Treatment Resistant Depression

Evaluation of Schemes of Administration of Intravenous Ketamine in Depression

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

Mexico, prevalence reported for major depressive disorder (MDD) is of 7.2%. It is currently in the top 5 causes of disability worldwide. One third of patients will not achieve remission after two treatments, being classified as treatment-resistant. In a neurochemical level, evidence shows dysregulation of the excitatory neurotransmitter Glutamate in patients with MDD. Chronic stress has been related to this dysregulation. Ketamine, has shown to regulate glutamatergic neurotransmission, and specially promote the release and production of neurotrophic factors key in the causes of MDD inhibited by glutamate dysregulation), and allow restoration of areas affected. Clinical studies of ketamine in MDD have shown robust, durable , and rapid effects (during the first 4-24 hours), allowing a great opportunity for patients who do not achieve benefits from antidepressants or patients with suicidal ideation . These results have been reported in metaanalysis. To our knowledge, there are no studies using Magnetic Resonance Spectroscopy, in areas related to MDD, after a series of ketamine administrations, which we think may show changes after this chronic administration and explain its antidepressant properties. Goals: Provide clinical evidence of responseas well as a neurological basis or biomarker of response to a series of ketamine infusions.

NCT ID: NCT03711019 Recruiting - Depression Clinical Trials

Efficacy of Convulsive Therapies During Continuation

CORRECT-C
Start date: October 22, 2018
Phase: N/A
Study type: Interventional

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.

NCT ID: NCT03701724 Recruiting - Clinical trials for Treatment-resistant Depression

Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression

ACOUSTIM
Start date: November 5, 2018
Phase: N/A
Study type: Interventional

Treatment resistant depression (TRD) is a frequent, debilitating condition mostly treated by antidepressants. Repeated magnetic transcranial stimulation (rTMS) has proven adjuvant efficacy in TRD in the acute phase of treatment with a very good tolerance and acceptability. Maintenance rTMS (mTMS) is a strategy consisting in adding regular single TMS sessions after response to an acute course in order to keep the benefit of initial treatment over several month or years. Demonstrating that rTMS is efficient to improve long-term prognosis and decrease economic burden would have a tremendous impact in clinical practice in psychiatry. Thus the investigator's aim is to analyze the long term impact of mTMS treatment on costs, but also quality of life and clinical issues.

NCT ID: NCT03684447 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Neural and Antidepressant Effects of Propofol

Start date: January 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study will compare the antidepressant effects of propofol versus a placebo intervention while measuring potential treatment-related biomarkers.

NCT ID: NCT03680781 Recruiting - Clinical trials for Treatment Resistant Depression

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

Start date: April 13, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.